1470 START001: a Phase 1/2 Study of Invikafusp Alfa (STAR0602), a First-in-class TCR Β Chain-Targeted Bispecific Antibody, As Monotherapy in Patients with Antigen-Rich Solid Tumors Resistant to Anti-Pd(l)1

James L Gulley, Ryan J Sullivan, Claire F Friedman, Guru P Sonpavde, Nicholas P Tschernia, Mercedes Herrera,Aurelien Marabelle, Shannon McCue, Karunya Srinivasan, Madan Katragadda, Jacques Moisan, Andrew Bayliffe, Rajesh Chopra, Kevin Chin, Zhen Su, Ke Liu, Lillian L Siu

Late-Breaking Abstracts（2024）

引用 0|浏览0

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要